Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/14548
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSongsurang K.
dc.contributor.authorPraphairaksit N.
dc.contributor.authorSiraleartmukul K.
dc.contributor.authorMuangsin N.
dc.date.accessioned2021-04-05T03:35:32Z-
dc.date.available2021-04-05T03:35:32Z-
dc.date.issued2011
dc.identifier.issn2536269
dc.identifier.other2-s2.0-79960414044
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/14548-
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-79960414044&doi=10.1007%2fs12272-011-0408-5&partnerID=40&md5=e7d846b3ebf9d17a775cc2cce58c4af9
dc.description.abstractThis work focused on a new technique for the preparation of doxorubicin (DOX) loaded chitosan (CS) nanoparticles (DOX-CS) - formation by electrospray ionization in the presence of tripolyphosphate (TPP) as the stabilizer. The working distance, needle gauge, flow rate, stirring rate, electrospraying voltage and DOX to CS molar ratio were sequentially and individually optimized and found to be a 26 gauge needle, an applied voltage of 13 kV, a flow rate of 0.5 mL/h, a working distance of 8 cm and a stirring rate of 400 rpm. The incorporation of chemically unchanged DOX with the CS into the particles was ascertained by Fourier transformed infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). Under these optimized conditions, the DOX-CS particles were found to be nanoparticles of approximately 300 - 570 (dry particles) or 530 - 870 nm diameter (hydrated particles), with a PDI and SPAN polydispersity indices of 0.97 - 0.82 and 0.62 - 0.64, respectively, for initial DOX loading levels of 0.25 - 1%, as determined by SEM and particle size analyzer, respectively. Moreover, a high encapsulation efficiency (EE) of DOX into the nanoparticles was attained, ranging from 63.4 to 67.9% EE at 1 to 0.25% DOX loading. Finally, the in vitro DOX release behaviors of the DOX-CS particles revealed a prolonged release of DOX over at least seven hours.
dc.subjectchitosan
dc.subjectdoxorubicin
dc.subjectnanoparticle
dc.subjecttripolyphosphate
dc.subjectarticle
dc.subjectdifferential scanning calorimetry
dc.subjectdrug delivery system
dc.subjectdrug release
dc.subjectelectrospray
dc.subjectencapsulation
dc.subjectin vitro study
dc.subjectinfrared spectroscopy
dc.subjectparticle size
dc.subjectthermogravimetry
dc.subjectAntibiotics, Antineoplastic
dc.subjectCalorimetry, Differential Scanning
dc.subjectChitosan
dc.subjectDoxorubicin
dc.subjectDrug Carriers
dc.subjectDrug Compounding
dc.subjectEquipment Design
dc.subjectMicroscopy, Electron, Scanning
dc.subjectNanoparticles
dc.subjectParticle Size
dc.subjectPolyphosphates
dc.subjectSolubility
dc.subjectSpectrometry, Mass, Electrospray Ionization
dc.subjectSpectroscopy, Fourier Transform Infrared
dc.subjectSurface Properties
dc.subjectThermogravimetry
dc.titleElectrospray fabrication of doxorubicin-chitosan-tripolyphosphate nanoparticles for delivery of doxorubicin
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationArchives of Pharmacal Research. Vol 34, No.4 (2011), p.583-592
dc.identifier.doi10.1007/s12272-011-0408-5
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.